CLINICAL RESEARCH
Monument Health

CLINICAL RESEARCH

Clinical trials are research studies conducted with patients to find effective ways to prevent, detect, diagnose and treat a variety of conditions. They are also used to study the psychological impact of different conditions and help improve patient comfort and quality of life.

To enroll in a trial, speak to your doctor or contact Monument Health Clinical Research at 605-755-4326 or research@monument.health.

Clinical Trials

    • A022102 – Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

    • ACHIEVE – A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

    • ARIA – Absorbable Antibacterial Soft Tissue Support in Breast Reconstruction With Infection Outcomes Assessment

    • ASCENT-05 – A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

    • ASPIRE – Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer

    • BiCazo – Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) – A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study

    • CIRCULATE-NORTH AMERICA – Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)

    • ComboMATCH – Molecular Analysis for Combination Therapy Choice (ComboMATCH)

    • COSMIC – Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

    • EAY191-E5 – A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

    • EQUATE – Effective Quadruplet Utilization after Treatment Evaluation (EQUATE): A randomized phase III trial for newly diagnosed Multiple Myeloma not intended for early autologous transplantation

    • HEAL-ABC – Harnessing E-Mindfulness Approaches for Living After Breast Cancer

    • LUNGMAP – A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LUNG-MAP Screening Study)

    • NRG-CC011 – Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial

    • PARAMUNE – Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

    • S1800E – A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

    • S2012 – Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

    • S2312 – A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

    • ShortStop-HER2 – ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

    • MAGICAL BTK – Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in the Treatment of Below the Knee Arterial Disease

    • SOS-AMI – Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

    • LIBREXIA-ACS – A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

    • Dal-GenE-2 – Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

    • ARTEMIS – A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

    • ACCLAIM Lp(a) – A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a)

    • EASi-HF – A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure
    • AZURE LDL – A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
    • AZURE Outcomes – A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
    • MARITIME-CV – Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
    • VICTORION-INTERVENTION – Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

    • ALLAY-HF – Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF
    • ALLAY-HFrEF – Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF

    • HERMES – A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
    • COMET-HF – Study with Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure with Severely Reduced Ejection Fraction
    • BalanceD-HF – Study to Evaluate the Effect of Balcinrenone/​Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
    • MARITIME HF – Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Clinical Research

We conduct clinical and specialty research in a wide variety of areas: treatment, prevention, diagnostic and screening, pharmaceutical trials, cardiac device trials and symptom management trials.

Volunteering for a research study means you will help develop medical therapies and treatments for the future. If are interested in participating in clinical trials, talk to your physician or contact Clinical Research at 605-755-4326.

Email: research@monument.health.

 

SPECIALTY RESEARCH

More From Monument Health